Delivering unique therapeutic and R&D monoclonal antibodies against membrane receptors and haptens

SYnAbs generates innovative monoclonal antibodies against:

SYnAbs unique technologies (SYnDNA vector, SYnCell syngeneic cell, in-house adjuvant) coupled with its strong expertise in breaking immune tolerance in proprietary rat-LOU species, ensure the generation of high specificity and higher affinity antibodies, benefiting from natural in-vivo maturation and targeting epitopes that are difficult to express in their native and functionally active conformation.

 

The application of such technologies have led, among others, to the generation of numerous functional therapeutic antibodies like : 





Raising antibodies against difficult to express antigens


Generating antibodies against conformation sensitive targets thanks to proprietary DNA, conformational peptide and whole cell immunization technologies


>99% success rate for small and poor immunogenic antigens and highly homologous epitopes


Extreme specificity monoclonal antibodies


Higher affinity monoclonal antibodies


Access to multiple immune repertoires and benefiting from natural in-vivo maturation


Additional epitope recognition in proprietary rat-LOU




Where to meet SYnAbs in 2022?

 

March 28th - March 31st

April 21st

June 13th - June 16th

Oct 12th - Oct 14th

Oct 24th - Oct 26th

Nov 2nd - Nov 4th

Nov 14th - Nov 16th

Nov 15th - Nov 18th

Dec 7th - Dec 9th

 

 

BioEurope Spring 

Innovation for Health

BIO International

BioJapan

BioEurope Fall

Festival of Biologics

PEGS

Medica

BioFIT

Download
SYnAbs ISO 9001 Certificate
Certificats Synabs 2021 (1).pdf
Adobe Acrobat Document 441.9 KB


Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

http://europe.wallonie.be


MENAC - Modifications Epigénétiques des Nucléosomes Associés au Cancer

 

Le projet MENAC a pour objectif de développer de tests innovants non invasifs pour la détection précoce 

de différents types de cancers.

 

Ce projet réalisé en partenariat par les sociétés Volition et Synabs passe par la création d'anticorps monoclonaux 

et la mise au point de nouveaux immuno-essais diagnostiques et théranostiques.

 

Subvention de 1.990.798€